Treatment of autoimmune disorders with CD154 antibodies
The present invention relates to a method of treating an autoimmune or inflammatory disease or a neurodegenerative disease with an antibody to CD154.
1. A method of treating systemic lupus erythematosus (SLE) comprising:
a) administering an initial loading dose of about 30 mg/kg of a monovalent antibody fragment binding specifically to CD154, the antibody fragment comprising a light chain variable region (LCVR) having a CDR1, a CDR2 and a CDR3 comprising the amino acid sequence of SEQ ID NOs:1, 2 and 3, respectively, and a heavy chain variable region (HCVR) having a CDR1, a CDR2 and a CDR3 comprising the amino acid sequence of SEQ ID NOs: 4, 5 and 6, respectively, to a human subject having SLE; and
b) about 2 weeks after the initial loading dose administering a further dose or doses of about 15 mg/kg of the monovalent antibody fragment binding specifically to CD154, with a frequency of about once every other week.
2. The method according to claim 1 , wherein the monovalent antibody fragment binding specifically to CD154 is administered to the human subject for at least 12 weeks.
3. The method according to claim 1 , wherein said monovalent antibody fragment specifically binding to CD154 contains the VL chain sequence shown in SEQ ID NO:7 and the VH chain sequence shown in SEQ ID NO:8.
4. The method according to claim 3 , wherein said monovalent antibody fragment specifically binding to CD154 has the light chain sequence shown in SEQ ID NO:9 and the heavy chain sequences shown in SEQ ID NO:10.
5. The method according to claim 4 , wherein said monovalent antibody fragment specifically binding to CD154 is a monovalent Fab′ having the light chain sequence shown in SEQ ID NO:9 and the heavy chain sequences shown in SEQ ID NO:10.
6. The method according to claim 5 , wherein said monovalent antibody fragment specifically binding to CD154 has
a) a maleimide group covalently linked to a single thiol group in the modified hinge region; a lysine residue is covalently linked to the maleimide group; and
b) a methoxypoly(ethyleneglycol) polymer having a molecular weight of approximately 20 KDa is attached to each of the amine groups on the lysine residue.
7. The method according to claim 1 , wherein said monovalent antibody fragment specifically binding to CD154 is administered to a subject having SLE and wherein the subject treated achieves an improvement from baseline of one or more of the indices selected from SLEDAI, BILAG and Global Physician assessment.
8. The method according to claim 7 , wherein the subject treated achieves a SLEDAI Responder Index 4 (SRI-4).
9. The method according to claim 7 , wherein said subject has SLE and wherein the subject treated achieves a 50% improvement from baseline of the SRI-50 index.
10. The method according to claim 7 , wherein said subject has SLE and achieves an increase of 20% from baseline or normalization of complement C3 and C4 concentration, or a reduction of 20% of anti-double stranded DNA titre in serum.
11. The method according to claim 7 , wherein said subject has SLE and wherein the subject reverts from seropositive to seronegative for anti-double stranded DNA antibodies.